KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges (2017 - 2026)

Amneal Pharmaceuticals has reported Amortization of Deferred Charges over the past 9 years, most recently at $3.7 million for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 45.5% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $22.4 million, down 22.91%, while the annual FY2025 figure was $22.4 million, 22.91% down from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $3.7 million at Amneal Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $8.0 million in Q3 2024 and troughed at $2.1 million in Q1 2023.
  • A 5-year average of $4.0 million and a median of $2.4 million in 2021 define the central range for Amortization of Deferred Charges.
  • Biggest five-year swings in Amortization of Deferred Charges: surged 240.03% in 2024 and later tumbled 45.5% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $2.3 million in 2021, then decreased by 9.61% to $2.1 million in 2022, then soared by 121.46% to $4.7 million in 2023, then skyrocketed by 46.16% to $6.8 million in 2024, then tumbled by 45.5% to $3.7 million in 2025.
  • Business Quant data shows Amortization of Deferred Charges for AMRX at $3.7 million in Q4 2025, $5.0 million in Q3 2025, and $6.9 million in Q2 2025.